12:00 AM
Oct 27, 2008
 |  BC Week In Review  |  Company News  |  Other News

Myriad Genetics diagnostic, neurology, cancer news

Following a review of strategic alternatives announced in August, Myriad decided to spin off its drug development business into a separate, publicly traded company called Myriad Pharmaceuticals Inc. The remaining molecular diagnostics...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >